Eiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

NASDAQ EIGR opened at $1.73 on Thursday. The company’s fifty day moving average is $4.77 and its two-hundred day moving average is $6.98. Eiger BioPharmaceuticals has a 52-week low of $1.10 and a 52-week high of $43.35. The firm has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.